← All trials
NCT00513617
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2004
- Primary completion
- Sep 1, 2007
- Completion date
- Jan 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 128
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of California, San FranciscoLead sponsor
- St. Jude Children's HospitalOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Thomas Jefferson UniversityOverall official - principal investigator
- Norton HealthcareOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- Children's Medical Center DallasOverall official - principal investigator
- University of Colorado, DenverOverall official - principal investigator
- Yeshiva UniversityOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- University of MississippiOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of OklahomaOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Boston UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.